# EcoR1 Capital: portfolio, investments and team

> EcoR1 Capital is a private equity based in United States. 33 investments on record, latest Jun 2020. Portfolio, stages, co-investors and team.

Source: https://millionrounds.com/fund/ecor1-capital (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# EcoR1 Capital

Filed with the SEC to raise a fund in Sep 2026, closing $812M. Last cheque observed Jun 2020.

Email

Quiet New fund $812M, Sept 2026 Private equity

Seed Series A Series B Biotech

Follow EcoR1 Capital and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Fecor1-capital)

Cheques on record

**0%** of best year **0** **cheques in 12 months**, 33 on record

Since the last cheque **2329** days **00** hrs **00** min **00** sec

Median round **$69M** Rounds led **0 of 33** Mostly in **United States, 91%**

Pitch EcoR1 Capital

## EcoR1 Capital highlights

- 01 33 rounds on record
- 02 Mostly Series B and Series A: 68% of its rounds

## What they do

> We are a San Francisco based biotech-focused investment fund. From their own website

- **Type:** Private equity (from a list, unverified)
- **Cheque size:** Not stated
- **Stages:** Seed Series A Series B Growth
- **Sectors:** Biotech
- **Based in:** San Francisco, United States
- **Cold pitches:** Accepted

## The record

Every round we can evidence, newest first **33 appearances**

- **2020** 1 round
- **Jun** **[Shattuck Labs, Inc.](https://millionrounds.com/company/shattuck-labs-inc)** Series B · US · Hatteras Venture Partners **$118M** With 8 others
- **2019** 5 rounds
- **Oct** **[Nuvation Bio](https://millionrounds.com/company/nuvation-bio)** Series A · US · FinSMEs **$275M** With 11 others
- **May** **[AlloVir](https://millionrounds.com/company/allovir)** Series B · US · Crunchbase News **$120M** With 9 others
- **May** **[ElevateBio](https://millionrounds.com/company/elevatebio)** Series A · US · Medcitynews **$150M** With 3 others
- **Mar** **[Prevail Therapeutics](https://millionrounds.com/company/prevail-therapeutics)** Series B · US · Medcitynews **$50M** With 10 others
- **Jan** **[Dewpoint Therapeutics](https://millionrounds.com/company/dewpoint-therapeutics)** Series A · US · FinSMEs **$60M** With 4 others
- **2018** 7 rounds
- **Oct** **[Avidity](https://millionrounds.com/company/avidity)** Series B · US · Aviditybiosciences **$16M** With 6 others
- **Sept** **[Morphic](https://millionrounds.com/company/morphic)** US · Endpts **$80M** With 2 others
- **Sept** **[Atreca](https://millionrounds.com/company/atreca)** Series C · US · FinSMEs **$125M** With 7 others
- **May** **[Accent](https://millionrounds.com/company/accent)** Series A · US · Xconomy **$40M** With 2 others
- **Mar** **[Unity](https://millionrounds.com/company/unity)** Series C · US · FinSMEs **$55M** With 11 others
- **Mar** **[Prevail](https://millionrounds.com/company/prevail)** Series A · FinSMEs **$75M** With 8 others
- **Feb** **[ORIC](https://millionrounds.com/company/oric)** Series C · US · FinSMEs **$50M** With 8 others
- **2017** 5 rounds
- **Dec** **[Relay](https://millionrounds.com/company/relay)** Series B · US · FinSMEs **$63M** With 5 others
- **Nov** **[Codiak](https://millionrounds.com/company/codiak)** Series C · US · FinSMEs **$77M** With 8 others
- **Nov** **[Arcus Biosciences](https://millionrounds.com/company/arcus-biosciences)** Series C · US · Businesswire **$107M** With 5 others
- **Jul** **[Kezar Life Sciences](https://millionrounds.com/company/kezar-life-sciences)** Series B · US · FinSMEs **$50M** With 7 others
- **Jan** **[Scholar Rock](https://millionrounds.com/company/scholar-rock)** Series C · US · FinSMEs **$47M** With 7 others
- **2015** 9 rounds
- **Dec** **[ORIC Pharmaceuticals](https://millionrounds.com/company/oric-pharmaceuticals)** Series B · US **$53M** With 5 others
- **Sept** **[Intellia Therapeutics](https://millionrounds.com/company/intellia-therapeutics)** Series B · US **$70M** With 7 others
- **Aug** **[Syndax Pharmaceuticals](https://millionrounds.com/company/syndax-pharmaceuticals)** Series C · US **$80M** With 12 others
- **Aug** **[Editas Medicine](https://millionrounds.com/company/editas-medicine)** Series B · US **$120M** With 14 others
- **Aug** **[Metacrine](https://millionrounds.com/company/metacrine)** Series A · US **$36M** With 3 others
- **Jun** **[Clementia Pharmaceuticals](https://millionrounds.com/company/clementia-pharmaceuticals)** Series B · CA **$60M** With 6 others
- **Jun** **[Kezar Life Sciences](https://millionrounds.com/company/kezar-life-sciences)** Series A · US **$23M** With 5 others
- **Mar** **[Kura Oncology](https://millionrounds.com/company/kura-oncology)** US **$60M** With 3 others
- **Mar** **[Collegium Pharmaceutical](https://millionrounds.com/company/collegium-pharmaceutical)** Venture · US **$50M** With 10 others
- **2014** 4 rounds
- **Sept** **[Scholar Rock](https://millionrounds.com/company/scholar-rock)** Series A · US **$20M** With 3 others
- **Sept** **[Flex Pharma](https://millionrounds.com/company/flex-pharma)** Venture · US **$40M** With 9 others
- **Mar** **[SAGE Therapeutics](https://millionrounds.com/company/sage-therapeutics)** Series C · GB **$38M** With 4 others
- **Jan** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$14M** With 6 others
- **2013** 1 round
- **Dec** **[Atara Biotherapeutics](https://millionrounds.com/company/atara-biotherapeutics)** Series B · US **$39M** With 5 others
- **2010** 1 round
- **Jan** **[Nabriva Therapeutics](https://millionrounds.com/company/nabriva-therapeutics)** Series B · AT · onbiovc.com **$22M** With 7 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **8 named**

BB **Brian Burkholder** Director i Filing they signed

CM **Cary Marr** Director i Filing they signed

ON **Oleg Nodelman** Manager of Biotech Opportunity GP, LLC, General Partner i Filing they signed

SM **Sarah Marriott** Chief Operating Officer of Biotech Opportunity GP, LLC, General Partner i Filing they signed

SP **Scott Perlen** Chief Financial Officer of Biotech Opportunity GP, LLC, General Partner i Filing they signed

TW **Tim Woolaver** Director i Filing they signed

TO **Trustee Oleg Nodelman** Manager i Form ADV

TS **Trustee Sarah Marriott** Member, CCO, COO i Form ADV

We also hold **14** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$3.4B** assets it manages Oct 2026

**Registered** investment adviser full reporting to the SEC

- **Legal name:** Ecor1 Capital, LLC
- **SEC number:** CRD 167121

Funds on its Form ADV

**3** private funds, **$5.0B** in gross assets · filed Oct 2024

Hedge **2** Venture **1**

- EcoR1 Capital Fund Qualified, L.P. *Hedge* 324 investors $4.6B
- EcoR1 Capital Fund, L.P. *Hedge* 87 investors $312M
- EcoR1 Venture Opportunity Fund, L.P. *Venture* 59 investors $85M

## What they claim to have backed

From their own portfolio page (on their website)

**27** of 42 we have independently watched raise

[Ajaxtherapeutics](https://millionrounds.com/company/ajax-therapeutics)[Akouos](https://millionrounds.com/company/akouos)[Aktisoncology](https://millionrounds.com/company/aktis-oncology)[Allovir](https://millionrounds.com/company/allovir)[Anagin](https://millionrounds.com/company/anagin)[Arcusbio](https://millionrounds.com/company/arcus-biosciences)[Atreca](https://millionrounds.com/company/atreca)[Atyrpharma](https://millionrounds.com/company/atyr-pharma)[Cellares](https://millionrounds.com/company/cellares)[Denalitherapeutics](https://millionrounds.com/company/denali-therapeutics)[Editasmedicine](https://millionrounds.com/company/editas-medicine)[Elevate](https://millionrounds.com/company/elevatebio)[Epikast](https://millionrounds.com/company/epikast)[Flex-pharma](https://millionrounds.com/company/flex-pharma)[Freenome](https://millionrounds.com/company/freenome)[Gossamerbio](https://millionrounds.com/company/gossamer-bio)[Kronosbio](https://millionrounds.com/company/kronos-bio)[Kuraoncology](https://millionrounds.com/company/kura-oncology)[Metacrine](https://millionrounds.com/company/metacrine)[Neurogene](https://millionrounds.com/company/neurogene)[Nuvationbio](https://millionrounds.com/company/nuvation-bio)[Oricpharma](https://millionrounds.com/company/oric-pharmaceuticals)[Pellepharm](https://millionrounds.com/company/pellepharm)[Prevailtherapeutics](https://millionrounds.com/company/prevail-therapeutics)[Scholarrock](https://millionrounds.com/company/scholar-rock)[Shattucklabs](https://millionrounds.com/company/shattuck-labs)[Unitybiotechnology](https://millionrounds.com/company/unity-biotechnology) Actiobiosciences Artivabio Atarabio Aviditynano Centessa Clementiapharma Codiakbio Collegiumpharma Kezarbio Kindredbio Kumquatbiosciences Morphimmune Nabriva Neogene Terremotobio

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

New fund on file

**$812M**

raised in Sept 2026

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Seed Series A Series B

Median round joined **$69M** the round, not its cheque

Led 0 of 33 rounds **0%**

- **Sole investor:** Never alone
- **Last cheque:** Jun 2020

Rounds by stage said on their site

- Series B said *13*
- Series A said *8*
- Series C *8*
- Venture *2*
- Seed said *-*
- Growth said *-*

Cheques by year Led Joined

2010 2020

Often in the room with

- [OrbiMed](https://millionrounds.com/fund/orbimed) 9
- [Alexandria Real Estate Equities](https://millionrounds.com/fund/alexandria) 7
- [Fidelity](https://millionrounds.com/fund/fidelity) 7
- [Omega Funds](https://millionrounds.com/fund/omega-funds) 7
- [Redmile Group](https://millionrounds.com/fund/redmile-group) 5
- [ARCH Venture Partners](https://millionrounds.com/fund/arch-venture-partners) 4

**Pitching EcoR1 Capital?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as EcoR1 Capital. A count of rooms they were both in, not a relationship either has claimed.

[**OrbiMed** Private equity **9** rounds together](https://millionrounds.com/fund/orbimed)[**Alexandria Real Estate Equities** VC firm **7** rounds together](https://millionrounds.com/fund/alexandria)[**Fidelity** VC firm **7** rounds together](https://millionrounds.com/fund/fidelity)[**Omega Funds** VC firm **7** rounds together](https://millionrounds.com/fund/omega-funds)[**Redmile Group** VC firm **5** rounds together](https://millionrounds.com/fund/redmile-group)[**ARCH Venture Partners** VC firm **4** rounds together](https://millionrounds.com/fund/arch-venture-partners)[**Arch** Hedge fund **3** rounds together](https://millionrounds.com/fund/arch)[**BVF Partners** VC firm **3** rounds together](https://millionrounds.com/fund/bvf-partners)[**Boxer Capital** VC firm **3** rounds together](https://millionrounds.com/fund/boxer-capital)[**Casdin Capital** VC firm **3** rounds together](https://millionrounds.com/fund/casdin-capital)[**Cormorant Asset Management** Private equity **3** rounds together](https://millionrounds.com/fund/cormorant-asset-management)[**Domain Associates** VC firm **3** rounds together](https://millionrounds.com/fund/domain-associates)

## Recently backed

The latest companies EcoR1 Capital put money into.

[**Nuvation Bio** $275M · Oct 2019](https://millionrounds.com/company/nuvation-bio)[**AlloVir** $120M · May 2019](https://millionrounds.com/company/allovir)[**ElevateBio** $150M · May 2019](https://millionrounds.com/company/elevatebio)[**Dewpoint Therapeutics** $60M · Jan 2019](https://millionrounds.com/company/dewpoint-therapeutics)[**Relay** $63M · Dec 2017](https://millionrounds.com/company/relay)[**Arcus Biosciences** $107M · Nov 2017](https://millionrounds.com/company/arcus-biosciences)

## Mentioned on podcasts

Episodes that name EcoR1 Capital in their description, not their title.

- [All-In](https://millionrounds.com/podcasts/all-in) 12 Jun 2026 · 1h 8m All-In's Best Ideas Pitch Competition: 4 Investors Present Their Top Trades Live Mentions [EcoR1 Capital](https://millionrounds.com/fund/ecor1-capital)[Multicoin Capital](https://millionrounds.com/fund/multicoin-capital)[Kyle Samani](https://millionrounds.com/person/kyle-samani) *+1* Apple PodcastsShow page

## Quick answers about EcoR1 Capital

### What does EcoR1 Capital invest in?

EcoR1 Capital invests most often at Series B and Series A (68% of the rounds on record), in sectors such as Biotech.

### How active is EcoR1 Capital?

33 investments on record, 0 of them in the last 12 months. The most recent was in Jun 2020.

### What has EcoR1 Capital invested in recently?

Its most recent investments on record: Shattuck Labs, Inc. (Series B, Jun 2020), Nuvation Bio (Series A, Oct 2019) and AlloVir (Series B, May 2019).

### How big are EcoR1 Capital's cheques?

The median round it joins is $69M.

### Does EcoR1 Capital lead rounds?

Rarely, if at all: none of its 33 investments on record names it as the lead.

### Where does EcoR1 Capital invest?

Most of the companies it backs are in the United States (91%).

### Is EcoR1 Capital investing now?

No investments in the last 12 months; the latest was in Jun 2020.

### Who does EcoR1 Capital invest alongside?

Most often OrbiMed (9 rounds together), Alexandria Real Estate Equities (7 rounds together) and Fidelity (7 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=ecor1-capital) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=ecor1-capital)